Richard Kim, MD

Where You Are:
Richard Kim, MD

Associate Member

Office  (813) 745-8459

Education And Training
  • Postdoctoral Fellow, Yale University Comprehensive Cancer Center, 2006 - Hematology and Medical Oncology
  • Resident, University of Illinois, 2003 - Internal Medicine
  • Intern, New York University Downtown Hospital, 2001 - Internal Medicine
  • MD, University of Miami School of Medicine, 2000


Dr. Richard Kim specializes in gastrointestinal oncology. As a clinical investigator, Dr. Kim’s main interest is conducting novel clinical trials. Currently he is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and phase II trials using novel targeted agents in gastrointestinal tumors, especially focusing on hepatobiliary and colon cancer.

  • Ashraf N, Kothari N, Kim R. Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: Beyond KRAS Testing. J Natl Compr Canc Ne. 2014 Oct;12(10):1433-1442. Pubmedid: 25313182.
  • Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 2014 Sep;18(9):1013-1021. Pubmedid: 23966224. Pmcid: PMC3780633.
  • Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology-Basel. 2014 Sep;87(2):125-132. Pubmedid: 25012155.
  • Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J Clin Pathol. 2014 Jul. Pubmedid: 25004944.
  • Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand?. World J Gastroenterol. 2014 May;20(18):5308-5319. Pubmedid: 24833861.
  • Ashraf N, Hoffe S, Kim R. French FNCLCC/FFCD 9703 study. Oncologist. 2014 Apr;19(4):431. Pubmedid: 24729607. Pmcid: PMC3983828.
  • Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Menon KN, Estfan B, Romero-Marrero C, Aucejo F. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2014 Mar;27(4):555-561. Pubmedid: 23758296.
  • Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. Crit Rev Oncol Hematol. 2013 Nov;88(2):416-426. Pubmedid: 23764501.
  • Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013 Aug;36(4):319-324. Pubmedid: 22547010.
  • Kim R, Mahipal A, Choi M, Saif MW. Biomarkers for Pancreatic Cancer: Is it Ready for Primetime?. JOP. 2013 Jul;14(4):309-311. Pubmedid: 23846914.
  • Kothari N, Saif MW, Kim R. First-line treatment for advanced pancreatic cancer. JOP. 2013 Mar;14(2):129-132. Pubmedid: 23474553.
  • Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, Liu X. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 2013 Jan;119(1):173-181. Pubmedid: 22736490.
  • Choi M, Razzaque S, Kim R. A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer. Clin Adv Hematol Oncol. 2012 Jul;10(7):442-451. Pubmedid: 22895284.
  • Kim R, Kubal T. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. Clin Colorectal Cancer. 2012 Jun;11(2):85-87. Pubmedid: 22169039.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247.
  • Choi M, Kim R, Saif MW. What options are available for refractory pancreatic cancer?. JOP. 2012 Mar;13(2):163-165. Pubmedid: 22406591.
  • Kim R, Byer J, Saif MW. BRCA and Pancreatic Cancer: Selection of Chemotherapy. JOP. 2012;13(2):180-181. Pubmedid: 22406596.
  • Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011 Dec;22(12):1697-1705. Pubmedid: 21983055.
  • Kim R, Menon N, Aucejo F. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. Med Oncol. 2011 Dec;28(4):1044-1047. Pubmedid: 20635167.
  • Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. Eur J Surg Oncol. 2011 Sep;37(9):791-797. Pubmedid: 21741199.
  • Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?. Liver Int. 2011 Sep;31(8):1081-1089. Pubmedid: 22008644.
  • Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, Liu X. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer. 2011 Jul;117(14):3126-3134. Pubmedid: 21264835.
  • Liu X, Jiang W, Aucejo F, Kim R, Miller C, Byrne M, Lopez R, Yerian L. Insulin-like growth factor I receptor β expression in hepatocellular carcinoma. Hum Pathol. 2011 Jun;42(6):882-891. Pubmedid: 21292299.
  • Kim R, Byrne MT, Tan A, Aucejo F. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Oncology (Williston Park). 2011 Mar;25(3):283-91, 295. Pubmedid: 21548473.
  • Kim R, Aucejo F. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. J Gastrointest Cancer. 2011 Mar;42(1):50-53. Pubmedid: 20714941.
  • Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?. Lancet Oncol. 2011 Jan;12(1):8-9. Pubmedid: 21050812.
  • Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology-Basel. 2011 Jan;79(1-2):62-66. Pubmedid: 21071991.
  • Kim R, Tsao R, Tan A, Byrne M, Almhanna K, Lazaryan A, Elson P, Pelley RJ. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg. 2010 Jul;14(7):1159-1169. Pubmedid: 20446118.
  • Phillips B, Kalady M, Kim R. BRAF testing in advanced colorectal cancer: is it ready for prime time?. Clin Adv Hematol Oncol. 2010 Jun;8(6):437-444. Pubmedid: 20733556.
  • Tan A, Aucejo F, Kim R. Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma?. Oncology. 2010 Jun;78(3-4):161-171. Pubmedid: 20530972.
  • Kim R, Tan A, Estfan B, Aucejo F. Adjuvant treatment after orthotopic liver transplantation: is it really necessary?. Oncology (Williston Park). 2009 Dec;23(14):1276-1281. Pubmedid: 20120841.
  • Kim R. Cetuximab and panitumumab: are they interchangeable?. Lancet Oncol. 2009 Dec;10(12):1140-1141. Pubmedid: 19875336.
  • Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncol. 2009 Sep;10(9):903-912. Pubmedid: 19717092.
  • Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009 Jun;35(4):322-327. Pubmedid: 19147294.
  • Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, Eghtesad B, Fung J, Miller C, Yerian L. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl. 2009 Feb;15(2):169-176. Pubmedid: 19177438.
  • Almhanna K, Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?. Oncology (Williston Park). 2008 Sep;22(10):1176-1183. Pubmedid: 18935928.
  • Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2008 Feb;23(2):139-145. Pubmedid: 17909820.
  • Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother. 2007 Nov;8(16):2719-2727. Pubmedid: 17956194.
  • Almhanna K, Kalmadi S, Pelley R, Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?. Oncology (Williston Park). 2007 Aug;21(9):1116-1122. Pubmedid: 17910314.
  • Kim R, Saif MW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?. JOP. 2007 May;8(3):279-288. Pubmedid: 17495356.
  • Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007 Mar;6(2):175-182. Pubmedid: 17367263.
  • Kim R, Chabot J, Saif MW. Adjuvant Treatment for Ampullary Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP. 2011;12(4):362-363. Pubmedid: 21737897.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions